Earnings Call Summary | Forian(FORA.US) Q3 2024 Earnings Conference
Earnings Call Summary | Forian(FORA.US) Q3 2024 Earnings Conference
The following is a summary of the Forian Inc. (FORA) Q3 2024 Earnings Call Transcript:
以下是Forian Inc. (FORA) 2024年第三季度業績發佈會會議記錄的總結:
Financial Performance:
財務表現:
Forian Inc. reported a third-quarter revenue of $4.7 million, down from $5.3 million year-over-year.
The company experienced a net loss of $0.2 million, compared to a net income of $4.3 million in the same period last year.
Adjusted EBITDA for the quarter was $0.2 million, a significant decrease from $1.1 million year-over-year.
Forian Inc.報告第三季度營業收入爲470萬美元,較去年同期的530萬美元下降。
公司在本季度經歷了20萬美元的淨虧損,而去年同期的凈利潤爲430萬美元。
本季度經調整的EBITDA爲20萬美元,較去年同期的110萬美元大幅下降。
Business Progress:
業務進展:
Forian intends to break out of its consistent revenue range in 2025, supported by increased sales momentum in health care services and life sciences.
The acquisition of Kyber Data Science is expected to expand Forian's addressable market and enhance its data science and predictive analytic capabilities.
Forian計劃在2025年突破其穩定的營業收入區間,這得益於醫療保健服務和生命科學銷售勢頭的增長。
收購Kyber Data Science預計將擴大Forian的可服務市場,並增強其數據科學和預測分析能力。
Opportunities:
機會:
The acquisition of Kyber Data Science targets new market opportunities by including financial service customers, which aligns well with Forian's life science customer base.
Forian continues to actively evaluate strategic opportunities, potentially including partnerships and acquisitions to enhance and expand their product portfolio and client base.
收購Kyber數據科學旨在通過包括金融服務客戶來把握新的市場機會,這與Forian的生命科學客戶基礎高度契合。
Forian繼續積極評估戰略機會,可能包括合作伙伴關係和收購,以增強和擴展其產品組合和客戶基礎。
Risks:
風險:
Revenue impacts from new sales have not been fully realized, posing a risk of delayed financial improvement.
Previous customer attrition and data disruptions have been significant headwinds, reflected in stagnant revenue growth.
新銷售的營業收入影響尚未完全實現,這帶來了財務改善延遲的風險。
客戶流失和數據中斷的問題一直是顯著的阻力,體現爲營業收入增長停滯不前。
More details: Forian IR
更多細節:Forian IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示:欲了解更全面的細節,請參閱IR網站。 文章僅供投資者參考,不構成任何指導或推薦建議。
譯文內容由第三人軟體翻譯。
評論(0)
請選擇舉報原因